Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ROIV Roivant Sciences Ltd.

Market Closed 07-31 16:00:00 EDT

33.91

-0.61

-1.77%

盘后33.91

+0.000.00%

19:50 EDT

High34.50	Low33.54	Vol5.40M
Open34.28	D1 Closing34.52	Amplitude2.78%
Mkt Cap24.50B	Tradable Cap19.13B	Total Shares722.41M
T/O182.78M	T/O Rate0.96%	Tradable Shares564.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":33.91,"timestamp":1785528000000,"preClose":34.52,"halted":0,"volume":5397093,"hourTrading":{"tag":"盘后","latestPrice":33.91,"preClose":33.91,"latestTime":"19:50 EDT","volume":230706,"amount":7823231.9297,"timestamp":1785541849255,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.017670915411355924,"floatShares":564000000,"shares":722406273,"eps":-0.539999,"marketStatus":"Market Closed","change":-0.61,"latestTime":"07-31 16:00:00 EDT","open":34.275,"high":34.5,"low":33.54,"amount":182779317.002529,"amplitude":0.02781,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.539999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785744000000},"marketStatusCode":7,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":34.52,"preHourTrading":{"tag":"盘前","latestPrice":34.45,"preClose":34.52,"latestTime":"09:29 EDT","volume":3133,"amount":107931.182671,"timestamp":1785504599999,"change":-0.07,"changeRate":-0.002028,"amplitude":0.002028},"postHourTrading":{"tag":"盘后","latestPrice":33.91,"preClose":33.91,"latestTime":"19:50 EDT","volume":230706,"amount":7823231.9297,"timestamp":1785541849255,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.2213009666753996,"impliedVol":0.5695,"impliedVolPercentile":0.9402},"requestUrl":"/m/hq/s/ROIV","defaultTab":"news","newsList":[{"id":"1154971062","title":"Earning Preview: Roivant Sciences Ltd. Q2 revenue is expected to decrease by 71.57%, and institutional views are cautious","url":"https://stock-news.laohu8.com/highlight/detail?id=1154971062","media":"Earnings Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1154971062?lang=en_us&edition=fundamental","pubTime":"2026-07-31 07:09","pubTimestamp":1785452943,"startTime":"0","endTime":"0","summary":"Abstract Roivant Sciences Ltd. will publish fiscal Q2 2026 results on August 06, 2026 Pre-Market; this preview summarizes consensus revenue, margins, net income trajectory, adjusted EPS, business-mix...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Earning Preview: Roivant Sciences Ltd. Q2 revenue is expected to decrease by 71.57%, and institutional views are cautious","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655369371","title":"Roivant Sciences price target raised to $35 from $31.50 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2655369371","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655369371?lang=en_us&edition=fundamental","pubTime":"2026-07-31 20:37","pubTimestamp":1785501458,"startTime":"0","endTime":"0","summary":"BofA raised the firm’s price target on Roivant Sciences (ROIV) to $35 from $31.50 and keeps a Neutral rating on the shares. The firm sees balanced ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-35-from-31-50-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-35-from-31-50-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTH","ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655845522","title":"Roivant President, Immunovant CEO Eric Venker Sells USD 6.99 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2655845522","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655845522?lang=en_us&edition=fundamental","pubTime":"2026-07-30 09:00","pubTimestamp":1785373245,"startTime":"0","endTime":"0","summary":"Roivant President, Immunovant CEO Eric Venker sells USD 6.99 million in common sharesRoivant Sciences President and Immunovant CEO Eric Venker sold 200,000 common shares on July 27 at a weighted avera","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL6q3Bq2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","ROIV","PTH","BK4585","BK4139","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655864551","title":"Roivant Sciences Announces Annual General Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2655864551","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655864551?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:02","pubTimestamp":1785322936,"startTime":"0","endTime":"0","summary":"Roivant Sciences announces annual general meeting of shareholdersRoivant Sciences will hold its annual general meeting in London on Sept. 16, 2026.Shareholders will vote to elect two Class II director","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDLZlYHy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654619030","title":"Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $59,700","url":"https://stock-news.laohu8.com/highlight/detail?id=2654619030","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654619030?lang=en_us&edition=fundamental","pubTime":"2026-07-25 05:59","pubTimestamp":1784930385,"startTime":"0","endTime":"0","summary":"Immunovant director Atul Pande disposes of 1,500 common shares for $59,700Immunovant director Atul Pande sold 1,500 shares on July 24, 2026 at USD 39.8.The sale followed the exercise of stock options ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDLbGPzpM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4585","BK4007","IMVT","BK4588","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653490775","title":"Immunovant Updates Financial Calendar with First-quarter Results Release and Business Update Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2653490775","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653490775?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:26","pubTimestamp":1784838369,"startTime":"0","endTime":"0","summary":"Immunovant updates financial calendar with first-quarter results release and business update callImmunovant to report fiscal Q1 results for the period ended June 30, 2026 on Aug. 6, 2026, before the m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL78ZZLp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4112","IMVT","BK4588","IE00BKPKM429.USD","PTH","SG9999014039.USD","BK4007","LU2095319765.USD","BK4139","BCDF","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","NDAQ","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","BK4585","SG9999014005.SGD","LU0314104364.USD","ROIV","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653775918","title":"Roivant to Report Q1 Results, Host Conference Call and Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2653775918","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653775918?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:20","pubTimestamp":1784838053,"startTime":"0","endTime":"0","summary":"Roivant to report Q1 results, host conference call and webcastRoivant schedules an 8:00 a.m. ET conference call webcast on Aug. 6, 2026 to report Q1 results ended June 30, 2026.Disclaimer:This news br","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL1SxkLW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","IE00B64PRP62.GBP","SG9999014039.USD","BK4585","BK4139","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","IE00BN0W2T93.GBP","LU2095319765.USD","BCDF","IE00BKPKM429.USD","ROIV","PTH","SG9999014005.SGD","SG9999014013.SGD","SG9999014021.USD","LU2210150020.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","NDAQ","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653773663","title":"Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653773663","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653773663?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:05","pubTimestamp":1784837100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nTUA2MLPQS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","ROIV","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653979877","title":"Immunovant Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2653979877","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653979877?lang=en_us&edition=fundamental","pubTime":"2026-07-23 04:11","pubTimestamp":1784751092,"startTime":"0","endTime":"0","summary":"Immunovant announces annual shareholder meetingImmunovant will hold its annual stockholders meeting virtually on Sept. 2, 2026.Shareholders will vote on electing three directors: Jacob Bauer, Douglas ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL5k6tVV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","BK4139","PTH","ROIV","IMVT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651417554","title":"Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents","url":"https://stock-news.laohu8.com/highlight/detail?id=2651417554","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651417554?lang=en_us&edition=fundamental","pubTime":"2026-07-16 20:16","pubTimestamp":1784204172,"startTime":"0","endTime":"0","summary":"Arbutus Biopharma  and its licensee Genevant Sciences, a subsidiary of Roivant Sciences , said Thursday they have filed three international patent infringement lawsuits against Pfizer , BioNTech  over lipid nanoparticle technology used in mRNA COVID-19 vaccines.The companies said they are seeking monetary damages and permanent injunctions covering Pfizer-BioNTech's COVID-19 vaccines and other allegedly infringing products.The new actions expand their existing US patent litigation in New Jersey involving five patents, they said.Separately, Arbutus said it received about $178 million from Moderna  on July 8 as its part of a global patent settlement and expects to receive a dividend from Genevant's parent in Q3.The company said it plans to return capital to shareholders through share repurchases of up to $230 million starting in Q3.Arbutus Biopharma shares were 3.7% higher in premarket trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4568","OZEM","IE0002270589.USD","LU1883839398.USD","IE00BLSP4452.SGD","MRNA","ABUS","LU1023059063.AUD","BK4535","BK4588","PTH","SG9999011175.SGD","MRNY","IE000M9KFDE8.USD","BK4532","IE00BLSP4239.USD","LGHT","MRNX","BK4007","WDNA","BK4139","LU1066051498.USD","LU0225771236.USD","LU1066053197.SGD","BNTX","LU0058720904.USD","LU0234572021.USD","LU0289739699.SGD","LU0985481810.HKD","SG9999013999.USD","BK4592","IE00B19Z3581.USD","LU1894683348.USD","LU0225284248.USD","LU0321505439.SGD","BK4548","LU0306806265.USD","LU1057294990.SGD","LU0321505868.SGD","PFE","BK4550","LU0170899867.USD","GNOM","BK4585","SGXZ57979304.SGD","IE00B3T34201.USD","SG9999003800.SGD","SG9999001176.USD","SG9999002232.USD","LU0122379950.USD","LU2596442595.SGD","LU0456855351.SGD","BK4501","ROIV","LU1894683264.USD","BK4581","BK4551","IE00B19Z3B42.SGD","BK4533","LU0868494617.USD","IDNA","SG9999001176.SGD","BK4534","BK4599","SG9999002224.SGD","LU0306807586.USD","IE00BBT3K403.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649867102","title":"Immunovant CEO Eric Venker Disposes of Common Shares Worth $3.46 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2649867102","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649867102?lang=en_us&edition=fundamental","pubTime":"2026-07-07 05:02","pubTimestamp":1783371732,"startTime":"0","endTime":"0","summary":"Immunovant CEO Eric Venker disposes of common shares worth $3.46 millionImmunovant CEO Eric Venker acquired 92,188 common shares on July 1, 2026 at $14.46 per share.He disposed of 86,629 shares on Jul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDLj4h1s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","ROIV","IMVT","PTH","BK4007","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648113639","title":"Roivant Director Meghan Fitzgerald Disposes of 10,000 Common Shares Worth $349,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2648113639","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648113639?lang=en_us&edition=fundamental","pubTime":"2026-07-03 07:04","pubTimestamp":1783033476,"startTime":"0","endTime":"0","summary":"Roivant director Meghan FitzGerald disposes of 10,000 common shares worth $349,000Roivant Sciences director Meghan FitzGerald exercised stock options for 10,000 common shares on June 30 at USD 8.8.Fit","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL835N5L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Director Meghan Fitzgerald Disposes of 10,000 Common Shares Worth $349,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648524102","title":"Roivant Sciences Director Melissa B. Epperly Disposes of Common Shares Worth $610,588.76","url":"https://stock-news.laohu8.com/highlight/detail?id=2648524102","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648524102?lang=en_us&edition=fundamental","pubTime":"2026-07-02 06:34","pubTimestamp":1782945297,"startTime":"0","endTime":"0","summary":"Roivant Sciences director Melissa B. Epperly disposes of common shares worth $610,588.76Roivant Sciences director Melissa B. Epperly sold 17,750 common shares on June 29, 2026, cutting her stake to 16","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL9X1V8V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences Director Melissa B. Epperly Disposes of Common Shares Worth $610,588.76","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648577593","title":"QVT Financial Reports Roivant Sciences Common Share Disposal Worth $48.57 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2648577593","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648577593?lang=en_us&edition=fundamental","pubTime":"2026-07-01 08:00","pubTimestamp":1782864006,"startTime":"0","endTime":"0","summary":"QVT Financial reports Roivant Sciences common share disposal worth $48.57 millionQVT Financial reported selling 1,438,163 Roivant Sciences common shares from June 26 to June 30.Sales were priced betwe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL4DQ200:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"QVT Financial Reports Roivant Sciences Common Share Disposal Worth $48.57 Million","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647535294","title":"Is Roivant Sciences (ROIV) Losing Its Defensive Status or Reframing Its Risk Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2647535294","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647535294?lang=en_us&edition=fundamental","pubTime":"2026-06-30 15:17","pubTimestamp":1782803829,"startTime":"0","endTime":"0","summary":"In late June 2026, Roivant Sciences Ltd. was removed from both the Russell 1000 Value-Defensive Index and the Russell 1000 Defensive Index, reflecting changes in these benchmarks’ constituent lists. \nThis dual index removal highlights how shifts in passive investment flows and institutional portfolio construction can influence how a biopharmaceutical company is perceived in the market. \nWe’ll now examine how Roivant’s removal from key Russell defensive indices may affect its existing...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/is-roivant-sciences-roiv-losing-its-defensive-status-or-refr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/is-roivant-sciences-roiv-losing-its-defensive-status-or-refr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","AIPO","CHAT","AGIX","BK4139","ROIV","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647300542","title":"Roivant President, CIO Mayukh Sukhatme Disposes of Common Shares Worth $34.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2647300542","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647300542?lang=en_us&edition=fundamental","pubTime":"2026-06-30 06:23","pubTimestamp":1782771819,"startTime":"0","endTime":"0","summary":"Roivant President, CIO Mayukh Sukhatme disposes of common shares worth $34.1 millionRoivant Sciences President and CIO Mayukh Sukhatme exercised 1 million stock options at $3.85 on June 25-26.He sold ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL2DKN99:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant President, CIO Mayukh Sukhatme Disposes of Common Shares Worth $34.1 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646974395","title":"Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $57,015","url":"https://stock-news.laohu8.com/highlight/detail?id=2646974395","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646974395?lang=en_us&edition=fundamental","pubTime":"2026-06-27 07:43","pubTimestamp":1782517435,"startTime":"0","endTime":"0","summary":"Immunovant director Atul Pande disposes of 1,500 common shares for $57,015Immunovant director Atul Pande exercised stock options for 1,500 common shares at $8.43 on June 26, 2026.Pande sold 1,500 comm","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDLSyS6p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","IMVT","BK4007","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646393286","title":"Roivant Sciences President and Immunovant CEO Eric Venker Disposes of Common Shares Worth $6.63 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2646393286","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646393286?lang=en_us&edition=fundamental","pubTime":"2026-06-27 06:14","pubTimestamp":1782512070,"startTime":"0","endTime":"0","summary":"Roivant Sciences President and Immunovant CEO Eric Venker disposes of common shares worth $6.63 millionRoivant Sciences President and Immunovant CEO Eric Venker exercised stock options for 200,000 com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL3gJsLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","IMVT","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644767441","title":"Immunovant director Atul Pande disposes of USD 51,030 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2644767441","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644767441?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:03","pubTimestamp":1781640228,"startTime":"0","endTime":"0","summary":"Immunovant director Atul Pande sold 1,500 shares on June 15, 2026 at USD 34.02.He also acquired 1,500 shares the same day via option exercise at USD 8.43.Derivative holdings included 69,681 stock options following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL6VlcnR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IMVT","BK4139","BK4007","ROIV","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643975945","title":"Piper Sandler Sticks to Their Buy Rating for Roivant Sciences (ROIV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643975945","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643975945?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:00","pubTimestamp":1781607627,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Roivant Sciences today and set a price target of $40.00. According to TipRanks, Rah...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-roivant-sciences-roiv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-roivant-sciences-roiv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://roivant.com;investor.roivant.com","stockEarnings":[{"period":"1week","weight":-0.0314},{"period":"1month","weight":-0.032},{"period":"3month","weight":0.2185},{"period":"6month","weight":0.5685},{"period":"1year","weight":1.985},{"period":"ytd","weight":0.5627}],"compareEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0366},{"period":"6month","weight":0.0796},{"period":"1year","weight":0.1819},{"period":"ytd","weight":0.0955}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.071559},{"month":2,"riseRate":0.333333,"avgChangeRate":0.052607},{"month":3,"riseRate":0,"avgChangeRate":-0.087601},{"month":4,"riseRate":0.833333,"avgChangeRate":0.021573},{"month":5,"riseRate":0.5,"avgChangeRate":0.035469},{"month":6,"riseRate":0.833333,"avgChangeRate":0.042574},{"month":7,"riseRate":0.666667,"avgChangeRate":0.026843},{"month":8,"riseRate":0.6,"avgChangeRate":0.00833},{"month":9,"riseRate":0.4,"avgChangeRate":0.013102},{"month":10,"riseRate":0.6,"avgChangeRate":0.101456},{"month":11,"riseRate":0.8,"avgChangeRate":0.02515},{"month":12,"riseRate":0.8,"avgChangeRate":0.23185}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction